3-phenylenediamine has been researched along with Diabetes Mellitus, Type 1 in 1 studies
*Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Głogowska-Szelag, J; Kajdaniuk, D; Karpe, J; Kos-Kudła, B; Marek, B; Nowak, K; Nowak, M; Siemińska, L; Swietochowska, E; Wielkoszyński, T | 1 |
1 other study(ies) available for 3-phenylenediamine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.
Topics: Adult; Age Factors; Aged; Antioxidants; Aryldialkylphosphatase; C-Reactive Protein; Ceruloplasmin; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Female; Humans; Male; Middle Aged; Oxidation-Reduction; Paraoxon; Phenylenediamines; Sex Factors | 2010 |